NCT06541652 A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
| NCT ID | NCT06541652 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Federation Francophone de Cancerologie Digestive |
| Condition | Hepatocholangiocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-03-26 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-03-26 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older, * with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma * diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort * for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies. Exclusion Criteria: * without social security * No access to tumor block
Contact & Investigator
jean-charles nault, Pr
PRINCIPAL INVESTIGATOR
Federation Francophone de Cancerologie Digestive
Frequently Asked Questions
Who can join the NCT06541652 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocholangiocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06541652 currently recruiting?
Yes, NCT06541652 is actively recruiting participants. Contact the research team at lila.gaba@u-bourgogne.fr for enrollment information.
Where is the NCT06541652 trial being conducted?
This trial is being conducted at Amiens, France, Angers, France, Beauvais, France, Besançon, France and 11 additional locations.
Who is sponsoring the NCT06541652 clinical trial?
NCT06541652 is sponsored by Federation Francophone de Cancerologie Digestive. The principal investigator is jean-charles nault, Pr at Federation Francophone de Cancerologie Digestive. The trial plans to enroll 150 participants.